Navigation Links
NIH awards UCI $10 million to study early-life origins of adolescent mental disorders
Date:6/11/2013

Irvine, Calif., June 11, 2013 With $10 million in new federal funding, UC Irvine researchers will study how maternal signals and care before and after birth may increase an infant's vulnerability to adolescent cognitive and emotional problems, such as risky behaviors, addiction and depression.

Led by child neurologist and neuroscientist Dr. Tallie Z. Baram, the UC Irvine team has received a five-year Silvio O. Conte Center grant from the National Institute of Mental Health, which is part of the National Institutes of Health. The funding program brings together researchers with diverse expertise to gain new knowledge and improve the diagnosis and treatment of mental health disorders.

The grant will support the creation of the Conte Center on Brain Programming in Mental Disorders at UC Irvine.

"We appreciate that the National Institute of Mental Health strategic plan recognizes that most neuropsychiatric disorders have origins early in life," said Baram, the Danette "Dee Dee" Shepard Chair in Neurological Studies. "This complex problem requires a multidisciplinary approach that involves both animal and human research. Investigators at UC Irvine have distinguished themselves in this area, and we believe that with the Conte Center funding, we can make major contributions to our understanding of this issue."

A large body of work has suggested that signals conveyed by a mother during fetal growth and the first few years after birth influence a baby's development and cognitive and emotional functioning. The UC Irvine team suspects that the patterns or rhythms of maternal signals, rather than their general quantity or quality, are key.

In neurobiology, it's well known that patterns of signals influence the function of single neurons. Recent research at UC Irvine suggests that patterns also matter on a "macro" scale of the entire brain. Specifically, animal studies have shown that consistent and predictable maternal sign
'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. U-M Water Center awards $570K in Great Lakes restoration grants
2. MARC Travel Awards announced for the ENDO 2013 95th Annual Meeting
3. MARC Travel Awards announced for the SDB 2013 72nd Annual Meeting
4. Center for Clinical and Translational Science awards new pilot grants
5. MARC travel awards announced for the 2013 60th Annual ACSM Meeting & 4th World Congress
6. Penn State Hass avocado research poster wins American Society For Nutrition Annual Awards
7. MARC travel awards announced for EB 2013
8. MARC travel awards announced for 2013 GSA Drosophila Research Conference
9. Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants
10. The 2013 HFSP postdoctoral fellowship awards
11. AAOS awards recognize innovative orthopaedic research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... for the first time that coenzyme Q10 offsets the cellular ... drugs - an increased risk of adult-onset diabetes. Statins ... world, able to reduce LDL, or "bad" cholesterol levels, and ... their role in raising the risk of diabetes has only ...
... 10, 2013  Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ... become a fully reporting public company with the Securities ... many highlights of the filing is a licensing agreement ... PVM International, Inc., has towards the company,s shareholders. The ...
... 2013, New York, NY A dozen Ludwig scientists ... basic and clinical cancer research at this week,s American ... in immunotherapy and epigenetics led the program with important ... "With new immunotherapy agents available to help ...
Cached Biology News:Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes 2Medbox Files Form 10 with SEC 2Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR 2
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
(Date:12/19/2014)... Arkansas (PRWEB) December 18, 2014 ... to locate its pilot production facility and future ... develop and produce innovative new materials that safely ... chosen not only because of its historic, strong ... leaders’ efforts to attract leading edge, technology-based companies ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... WALTHAM, Mass. , May 24 Repligen ... of Orphan Products Development of the Food and Drug Administration ... histone deacetylase 3 (HDAC-3) inhibitor for the treatment of Friedreich,s ... of marketing exclusivity in the United States if ...
... 24 MO BIO Laboratories, Inc., the leader ... the launch of a groundbreaking new product, PowerLyzer™ 24 ... homogenization and lysis of any biological sample.  The PowerLyzer™ ... analysis faster, minimize cross-contamination, and maintain sample integrity. ...
... CLEVELAND, Ohio , May 24, 2010 Simbionix ... medical professionals and the healthcare industry, is launching,two new hands-on training systems- ... revealed for the first time at,the AUA annual meeting in San ... , ...
Cached Biology Technology:Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 3Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 4MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 3